Sehn, L. H. Et Al. 2022. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data. Blood Advances , vol.6, no.2 , 533-543.

Sehn, L. H., Hertzberg, M., Opat, S., Herrera, A. F., Assouline, S., Flowers, C. R., ... Kim, T. M.(2022). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data. Blood Advances , vol.6, no.2, 533-543.

Sehn, Laurie Et Al. "Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data," Blood Advances , vol.6, no.2, 533-543, 2022

Sehn, Laurie H. Et Al. "Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data." Blood Advances , vol.6, no.2, pp.533-543, 2022

Sehn, L. H. Et Al. (2022) . "Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data." Blood Advances , vol.6, no.2, pp.533-543.

@article{article, author={Laurie H. Sehn Et Al. }, title={Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data}, journal={Blood Advances}, year=2022, pages={533-543} }